Adia Nutrition, Inc. (OTC: ADIA)

ADIA Nutrition, Inc. focuses on delivering regenerative medicine therapies and nutritional supplements through its medical clinics, laboratory operations, and supplement investments. The company aims to revolutionize patient care by providing autologous hematopoietic stem cell transplantation and umbilical cord stem cell treatments. It operates a clinic under the brand Adia Med that performs these procedures for individuals seeking advanced therapeutic options. Through its subsidiary Adia Labs, the company processes and sells biologic products derived from perinatal tissues. Additionally, ADIA Nutrition holds an equity position in a supplement enterprise to broaden its portfolio into consumer health products.

Revenue is generated primarily from three sources: clinical service fees, biologic product sales, and supplement-related earnings. Patients receiving treatments at Adia Med clinics are charged for procedures such as autologous hematopoietic stem cell transplantation and umbilical cord stem cell infusions. Adia Labs sells its processed biologic products, including AdiaVita and AdiaLink, to healthcare providers and regenerative medicine facilities throughout the United States. The supplement business contributes revenue through the 18% equity stake in Cement Factory, LLC, which manufactures and distributes organic premium vitamins and nutraceuticals. Direct-to-consumer online sales of these supplements also add to the company’s top line. Additionally, the company may earn licensing or service fees when its technologies are used by partner clinics.

The company operates through the following segments.

• Adia Med: Operates clinics that provide autologous hematopoietic stem cell transplantation and umbilical cord stem cell treatments to patients seeking regenerative therapies.

• Adia Labs: Procurement, processing, and sale of biologic products such as AdiaVita and AdiaLink to healthcare providers and regenerative medicine facilities across the United States.

• Supplement Business: Holds an 18% equity interest in Cement Factory, LLC and supports the development and distribution of organic premium supplements to consumers through online and retail channels.

The regenerative tissue products market is moderately fragmented, with approximately 30 to 50 competitors offering amniotic‑ or umbilical‑cord‑based therapies. ADIA Nutrition differentiates itself by holding FDA registration for its human cells, tissues and cellular and tissue‑based products under Section 361 of the Public Health Service Act and maintaining AATB accreditation for its laboratory processes. Its proprietary formulations guarantee a minimum of 100 million viable stem cells and 3 trillion exosomes per unit, providing a measurable potency advantage over many rivals. While the broader pharmaceutical industry does not currently compete in this niche, the company anticipates future interest as regenerative medicine gains wider acceptance. These factors, including regulatory compliance, product consistency, and a vertically integrated model from lab to clinic, constitute ADIA Nutrition’s competitive advantages.

The company serves patients undergoing stem cell therapies at its Adia Med clinics, healthcare providers that administer its biologic products, and consumers who purchase its supplement offerings. Specific customer names are not disclosed in the filing, but the clientele includes individuals seeking treatment for orthopedic conditions, pain management, wound repair, and anti‑aging applications. Regenerative medicine facilities and clinics across the United States represent a significant portion of Adia Labs’ product sales. Direct‑to‑consumer supplement buyers access the products through the Cement Factory online platform and related channels.